Our site uses cookies to offer a better navigation functionality, including "third party" cookies and "profiling cookies" designed to send on-line commercial communications in line with the preferences expressed by the user while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here to disable them. Upon proceeding with browsing this website, you will be consenting to the use of cookies.
Characterization of the novel antibody drug conjugate MEN1309 and its target antigen Ly75
AACR Annual Meeting-2017, Washington DC, April 1-5, 2017
The novel anti-CD205 Antibody Drug Conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL).
AACR Annual Meeting-2017, Washington DC, April 1-5, 2017
MEN1309, a novel antibody drug conjugate (ADC) targeting Ly75 antigen, induces complete responses in several xenografts of solid tumors.
AACR Annual Meeting-2017, Washington DC, April 1-5, 2017

Therapeutic Areas

 

Discover all of Menarini's products marketed in Italy.

READ MORE »

Diagnostics

 

Advanced Technology

READ MORE »

The Menarini Group

 

Discover the leading Italian pharmaceutical company in the world.

READ MORE »

Quality first

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »